CSIMarket
 


Travere Therapeutics Inc   (TVTX)
Other Ticker:  
 

Travere Therapeutics Inc 's Total Debt to Equity

TVTX's quarterly Total Debt to Equity and Total Debt, Equity growth




TVTX Total Debt to Equity (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity Change -67.25 % -52.84 % -42.61 % 0.23 % -3.54 %
Y / Y Total Debt Change 67.69 % 69.65 % 71.65 % 6.55 % 6.52 %
Total Debt to Equity MRQ 3.73 2.39 1.8 0.75 0.73
Overall Ranking # # # # #
Seq. Equity Change -35.76 % -24.71 % -31.1 % -1.71 % -7.5 %
Seq. Total Debt Change 0.11 % 0.1 % 65.21 % 1.29 % 1.28 %



Total Debt to Equity third quarter 2022 Comment
Due to net new borrowings of 0.11%, Total Debt to Equity detoriated to 3.73, above company's average Total Debt to Equity.

Within Major Pharmaceutical Preparations industry Travere Therapeutics Inc achieved lowest Total Debt to Equity. While total ranking remained unchanged compare to previous quarter at no. .

Explain Debt to Equity Ratio?
Where is TVTX most successful ?
Total Debt to Equity TVTX on the trailing twelve month basis
Total Debt to Equity third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Total Debt to Equity Statistics
High Average Low
0 0 0
 




Financial Statements
Travere Therapeutics Inc 's Equity $ 101 Millions Visit TVTX's Balance sheet
Travere Therapeutics Inc 's Total Debt $ 375 Millions Visit TVTX's Balance sheet
Source of TVTX's Sales Visit TVTX's Sales by Geography


Cumulative Travere Therapeutics Inc 's Total Debt to Equity

TVTX's Total Debt to Equity for the trailling 12 Months

TVTX Total Debt to Equity

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity TTM Growth -67.25 % -52.84 % -42.61 % 0.23 % -3.54 %
Y / Y Total Debt TTM Growth 67.69 % 69.65 % 71.65 % 6.55 % 6.52 %
Total Debt to Equity TTM 1.76 1.23 0.91 0.68 0.67
Total Ranking TTM # # # # #
Seq. Equity TTM Growth -35.76 % -24.71 % -31.1 % -1.71 % -7.5 %
Seq. Total Debt TTM Growth 0.11 % 0.1 % 65.21 % 1.29 % 1.28 %


TTM Total Debt to Equity Comment
On the trailing twelve months basis Due to net new borrowings of 0.11%, Total Debt to Equity improved to 1.76, above Travere Therapeutics Inc 's average Total Debt to Equity.
Total Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry TVTX recorded the lowest Total Debt to Equity. While total ranking remained unchanged compare to previous quarter at no. 0.

Explain Debt to Equity Ratio?
Where is TVTX most successful ?
Total Debt to Equity TVTX on the trailing twelve month basis

TTM Total Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Within the Market # 0


TTM Total Debt to Equity Statistics
High Average Low
0.09 0.05 0.02
(Mar 31 2019)   (Dec 31 2019)




Companies with similar Total Debt to Equity in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Total Debt to EquitySep 30 2022 MRQ Total DebtSep 30 2022 MRQ Equity
Jaguar Health inc   8.82 $ 31.743  Millions$ 3.599  Millions
Molecular Templates Inc   8.66 $ 35.940  Millions$ 4.152  Millions
Heron Therapeutics Inc   6.65 $ 149.234  Millions$ 22.450  Millions
Evelo Biosciences Inc   5.01 $ 46.745  Millions$ 9.334  Millions
Akebia Therapeutics Inc   4.76 $ 65.947  Millions$ 13.853  Millions
Madrigal Pharmaceuticals Inc   4.59 $ 48.983  Millions$ 10.670  Millions
Puma Biotechnology Inc   4.42 $ 97.994  Millions$ 22.155  Millions
Abbvie Inc   4.34 $ 69,606.000  Millions$ 16,027.000  Millions
Travere Therapeutics Inc   3.73 $ 375.117  Millions$ 100.676  Millions
Collegium Pharmaceutical inc   3.67 $ 723.569  Millions$ 197.194  Millions
Sarepta Therapeutics Inc   3.58 $ 1,542.770  Millions$ 430.840  Millions
Intercept Pharmaceuticals inc   3.09 $ 332.308  Millions$ 107.676  Millions
Amicus Therapeutics inc   2.95 $ 391.319  Millions$ 132.565  Millions
Seelos Therapeutics Inc   2.72 $ 21.397  Millions$ 7.879  Millions
Societal Cdmo Inc   2.71 $ 95.478  Millions$ 35.234  Millions
Revance Therapeutics Inc   2.60 $ 378.889  Millions$ 145.713  Millions
Xeris Biopharma Holdings Inc   2.52 $ 138.507  Millions$ 55.040  Millions
Evolus Inc   2.45 $ 71.712  Millions$ 29.220  Millions
Teva Pharmaceutical Industries Limited  2.23 $ 21,266.000  Millions$ 9,519.000  Millions
Biovie Inc   2.13 $ 12.725  Millions$ 5.961  Millions
Jazz Pharmaceuticals Plc  2.09 $ 5,726.814  Millions$ 2,745.194  Millions
Athenex Inc   2.06 $ 14.927  Millions$ 7.236  Millions
Scynexis Inc   1.99 $ 34.162  Millions$ 17.209  Millions
Phibro Animal Health Corporation  1.78 $ 467.158  Millions$ 262.756  Millions
G1 Therapeutics Inc   1.67 $ 76.558  Millions$ 45.965  Millions
Mallinckrodt Plc  1.66 $ 3,078.400  Millions$ 1,849.100  Millions
China Pharma Holdings Inc   1.60 $ 4.550  Millions$ 2.835  Millions
Eli Lilly And Company  1.56 $ 15,888.400  Millions$ 10,165.900  Millions
Zoetis Inc   1.41 $ 6,563.000  Millions$ 4,662.000  Millions
9 Meters Biopharma Inc   1.37 $ 18.390  Millions$ 13.461  Millions

Date modified: 2022-10-28T16:01:35+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

TVC's Profile

Stock Price

TVC's Financials

Business Description

Fundamentals

Charts & Quotes

TVC's News

Suppliers

TVC's Competitors

Customers & Markets

Economic Indicators

TVC's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071